# Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

> **NCT05497843** · PHASE2 · COMPLETED · sponsor: **Chipscreen Biosciences, Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Chiauranib

## Key facts

- **NCT ID:** NCT05497843
- **Lead sponsor:** Chipscreen Biosciences, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-25
- **Primary completion:** 2025-01-03
- **Final completion:** 2025-01-03
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05497843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05497843, "Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05497843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*